Allogeneic iPSC-derived cardiomyocyte spheroids
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Allogeneic iPSC-derived cardiomyocyte spheroids, covering 2026-01-16 to 2026-01-16. Get the full timeline:
Most recent: Clinical Trial Update: Endocardial Delivery for Myocardial Regeneration Using Allogeneic iPSC-derived Cardiomyocyte Spheroids for HF With Systolic Dysfunction (EMERALD Study) [Phase 1, Phase 2]